Virazole

(Ribavirin)

ApprovedSmall molecule

Ribavirin is an antiviral medication used to treat certain viral infections, most commonly hepatitis C (often combined with other drugs) and severe respiratory syncytial virus (RSV) infection in hospitalized patients.[2] Virazole is currently approved and in use across 22 indications[4].[1]

Virazole is one of 458 small molecule programs targeting Severe Acute Respiratory Syndrome. It is currently in Approved.

Indications

517

Total Trials

Active Trials

457

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Severe Acute Respiratory SyndromeActive, not recruiting

Cirrhosis of LiverActive, not recruiting

Head and Neck Malignant NeoplasiaActive, not recruiting

Chronic Hepatitis B Virus InfectionApproved

Hantavirus Pulmonary SyndromeActive, not recruiting

Viral DiseaseActive, not recruiting

FibrosisActive, not recruiting

Hepatitis B Virus InfectionApproved

HIV InfectionApproved

Type 1 Diabetes MellitusApproved

Severe Acute Respiratory SyndromePreclinical

Active, not recruiting

Cirrhosis of LiverApproved

Active, not recruiting

Head and Neck Malignant NeoplasiaPreclinical

Active, not recruiting

Chronic Hepatitis B Virus InfectionApproved

Approved

Hantavirus Pulmonary SyndromePreclinical

Active, not recruiting

Viral DiseaseApproved

Active, not recruiting

FibrosisApproved

Active, not recruiting

Hepatitis B Virus InfectionApproved

Approved

HIV InfectionApproved

Approved

Type 1 Diabetes MellitusApproved

Approved

Showing 10 of 22 indications

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Virazole

CConrado Roberto Hoffmann Filho

Approved

19 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 6

Valium

Akero Therapeutics

Preclinical

2 7

Lotemax

PPharmos

Preclinical

1 8

Norpramin

VValidus Pharmaceuticals

Preclinical

1 9

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis70 trials

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Terminated·DDebiopharm International SA·Phase 3·NCT01500772·6 enrolled

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00423670·765 enrolled

Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158496·100 enrolled

Show 67 more trials

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT01833533·305 enrolled

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT01726946·10 enrolled

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Completed· AbbVie logo

AbbVie··NCT02803138·256 enrolled

A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)

Completed· Roche logo

Roche·Phase 4·NCT02641379·737 enrolled

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Completed· Roche logo

Roche··NCT01447446·4,442 enrolled

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Completed· Roche logo

Roche··NCT02557646·697 enrolled

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT00780416·189 enrolled

Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C

Completed·RRomark Laboratories L.C.·Phase 2/3·NCT00421434·121 enrolled

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Completed· GSK logo

GSK·Phase 2·NCT01439373·16 enrolled

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 4·NCT01467492·121 enrolled

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01390844·282 enrolled

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Completed· Roche logo

Roche··NCT00700401·262 enrolled

Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)

Completed· Merck & Co. logo

Merck & Co.··NCT00863109·133 enrolled

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn· Roche logo

Roche·Phase 2·NCT01579019

Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00705666·789 enrolled

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Completed· Roche logo

Roche·Phase 4·NCT01447420·129 enrolled

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02216422·36 enrolled

Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Unknown status·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00148837·112 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Completed· Roche logo

Roche·Phase 4·NCT00077649·188 enrolled

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Completed· Roche logo

Roche·Phase 4·NCT01429792·1,013 enrolled

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

Completed· Roche logo

Roche·Phase 4·NCT01585324·30 enrolled

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Completed· Roche logo

Roche·Phase 4·NCT01591460·165 enrolled

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02167945·615 enrolled

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Withdrawn· Roche logo

Roche·Phase 3·NCT01296971

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00705432·1,472 enrolled

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Completed· Roche logo

Roche·Phase 2·NCT01903954·283 enrolled

Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00148863·65 enrolled

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 2/3·NCT03362814·425 enrolled

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00088504·315 enrolled

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT02243293·694 enrolled

Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT00687544·11 enrolled

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Completed·TTibotec BVBA·Phase 2·NCT00528528·166 enrolled

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00910624·168 enrolled

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00160251·357 enrolled

PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)

Completed·SSchering-Plough·Phase 4·NCT00724620·103 enrolled

Completed· AbbVie logo

AbbVie·Phase 3·NCT02219490·1,596 enrolled

Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT02105454·79 enrolled

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Completed· Roche logo

Roche·Phase 2·NCT01628094·110 enrolled

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Completed· Roche logo

Roche·Phase 2·NCT01057667·168 enrolled

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

Completed·NNanogen Pharmaceutical Biotechnology Joint Stock Company·Phase 4·NCT06922643·100 enrolled

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01852604·143 enrolled

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00302081·696 enrolled

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01525628·72 enrolled

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

Completed·DDebiopharm International SA·N/A·NCT01970904·147 enrolled

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT00851890·30 enrolled

A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

Terminated· Roche logo

Roche·Phase 3·NCT02791256·23 enrolled

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01628692·230 enrolled

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Completed· Roche logo

Roche·Phase 2·NCT01483742·43 enrolled

Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01678131·31 enrolled

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Completed·AAlios Biopharma Inc.·Phase 2·NCT01790100·20 enrolled

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01498068·36 enrolled

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01142700

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Completed· AbbVie logo

AbbVie·Phase 3·NCT01854528·148 enrolled

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01629732

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01353911·368 enrolled

A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C

Completed· Roche logo

Roche·Phase 4·NCT00800748·372 enrolled

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02023112·171 enrolled

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

Withdrawn·FFundacion SEIMC-GESIDA·Phase 4·NCT03105349

Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1·NCT01547312

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Completed· Roche logo

Roche·Phase 2·NCT01482390·80 enrolled

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01544920·737 enrolled

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

Unknown status·—·Phase 4·NCT01731301·20 enrolled

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01710501·87 enrolled

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00880763·90 enrolled

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Completed· AbbVie logo

AbbVie··NCT02581163·314 enrolled

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT00310336·30 enrolled

Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)

Completed· Merck & Co. logo

Merck & Co.··NCT00725751·353 enrolled

Hepatitis C56 trials

Study of Oral Treatments for Hepatitis C

Completed·UUniversity of Florida·Phase 4·NCT02786537·1,275 enrolled

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Completed· Roche logo

Roche··NCT02556307·270 enrolled

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT01468584·10 enrolled

Show 53 more trials

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Terminated·CConatus Pharmaceuticals Inc.·Phase 2·NCT01273064·114 enrolled

The SIM-SOF Trial for Hepatitis C

Completed·CCenter For Hepatitis C, Atlanta, GA·Phase 4·NCT02168361·93 enrolled

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01448044·152 enrolled

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

Completed·CCarelon Research·Phase 2·NCT00502788·21 enrolled

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Completed·TTibotec BVBA·Phase 3·NCT00703118·663 enrolled

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01440595·5 enrolled

Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Terminated· Merck & Co. logo

Merck & Co.··NCT00723879·115 enrolled

Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00704522·601 enrolled

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)

Completed· Merck & Co. logo

Merck & Co.··NCT00727259·1,995 enrolled

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01704755·381 enrolled

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT02068222·10 enrolled

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Completed· AbbVie logo

AbbVie·Phase 2·NCT02493855·46 enrolled

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Completed· AbbVie logo

AbbVie·Phase 2·NCT01995071·89 enrolled

Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C

Completed·GGöteborg University·Phase 4·NCT00910975·100 enrolled

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00980330·463 enrolled

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

Completed·KKarolinska Institutet·N/A·NCT00909129·25 enrolled

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Completed· AbbVie logo

AbbVie·Phase 2·NCT01314261·37 enrolled

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01289782·395 enrolled

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01358864·678 enrolled

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Completed· Gilead logo

Gilead·Phase 2·NCT01356160·351 enrolled

An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01725529·457 enrolled

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01012895·215 enrolled

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT01466192·108 enrolled

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01290679·393 enrolled

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01281839·394 enrolled

Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4

Unknown status·ZZagazig University··NCT02772744·250 enrolled

Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)

Completed·SSchering-Plough··NCT00705263·113 enrolled

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00947349·22 enrolled

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01292239·183 enrolled

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00704405·285 enrolled

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01290731·49 enrolled

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01366638·79 enrolled

Australian Trial in Acute Hepatitis C

Completed·KKirby Institute·Phase 4·NCT00192569·167 enrolled

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

Terminated·UUniversity of Colorado, Denver·Phase 3·NCT02455167·9 enrolled

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00983853·62 enrolled

A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01288209·106 enrolled

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01434498·163 enrolled

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01353248·141 enrolled

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01471574·549 enrolled

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT00372385·334 enrolled

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

Completed·RRomark Laboratories L.C.·Phase 2·NCT00637923·112 enrolled

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 1·NCT02128217·44 enrolled

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

Unknown status·IIRCCS San Raffaele·Phase 3·NCT00437684·50 enrolled

Combination Drug Therapy for Patients With Hepatitis C

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00001729·120 enrolled

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Completed·KKirby Institute·Phase 3·NCT02634008·83 enrolled

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01455090·320 enrolled

DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)

Completed·AANRS, Emerging Infectious Diseases·Phase 4·NCT03537196·979 enrolled

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00122629·405 enrolled

Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

Terminated·BBioLineRx, Ltd.·Phase 1/2·NCT01833845·4 enrolled

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

Withdrawn·UUniversity of Vermont·Phase 4·NCT01415141

In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

Completed·FFremantle Hospital and Health Service··NCT01726400·15 enrolled

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00008463·132 enrolled

The Effect of Adding Metformin to the Treatment of Hepatitis C

Completed·TTehran University of Medical Sciences·Phase 4·NCT00560690·140 enrolled

Chronic Hepatitis C Virus Infection9 trials

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT02356562·29 enrolled

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02723084·136 enrolled

A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT02292719·70 enrolled

Show 6 more trials

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT01685203·316 enrolled

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02609659·105 enrolled

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01241760·744 enrolled

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Terminated·MM.D. Anderson Cancer Center·Phase 4·NCT05717400·2 enrolled

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02219477·36 enrolled

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01072695·46 enrolled

Treatment6 trials

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

Completed· AbbVie logo

AbbVie·Phase 3·NCT02399345·10 enrolled

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00991289·68 enrolled

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

Completed·MM.D. Anderson Cancer Center·Phase 4·NCT00500578·51 enrolled

Show 3 more trials

A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001015·96 enrolled

The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

Withdrawn·TTCM Biotech International Corp.·Phase 3·NCT01890200

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01849562·30 enrolled

Liver Transplant5 trials

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02032875·116 enrolled

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT01467505·61 enrolled

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01571583·74 enrolled

Show 2 more trials

Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT01463956·58 enrolled

Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

Withdrawn·TThe University of Texas Health Science Center, Houston·Phase 4·NCT00167557

33 more indications

Hepatitis C Virus Infection5 trials

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01371578·163 enrolled

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02194998·46 enrolled

Treatment of Recently Acquired Hepatitis C Virus Infection

Completed·KKirby Institute·Phase 4·NCT01336010·82 enrolled

Show 2 more trials

Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01700179·8 enrolled

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Completed·TTrek Therapeutics, PBC·Phase 2·NCT02716428·25 enrolled

Efficacy and Safety4 trials

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 2·NCT03020004·70 enrolled

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01797848

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Completed·DDebiopharm International SA·Phase 2·NCT01183169·459 enrolled

Show 1 more trial

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

Completed·DDongguan HEC TaiGen Biopharmaceuticals Co., Ltd.·Phase 3·NCT04155515·370 enrolled

Fasting Conditions3 trials

Ribavirin 200 mg Tablets Under Non-Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00835536·27 enrolled

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00960479·38 enrolled

Ribavirin 200 mg Tablets Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00835146·28 enrolled

TED3 trials

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01371604·68 enrolled

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00724373·442 enrolled

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Completed·AANRS, Emerging Infectious Diseases·Phase 2·NCT02107365·60 enrolled

Combination Therapy3 trials

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01732796·470 enrolled

Dose Ranging of GSK2336805 in Combination Therapy

Completed· GSK logo

GSK·Phase 2·NCT01648140·286 enrolled

A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000833·20 enrolled

Phase II2 trials

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01573351·398 enrolled

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01581203·748 enrolled

Randomized2 trials

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Completed· AbbVie logo

AbbVie·Phase 2·NCT01074008·74 enrolled

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Completed·UUniversity of Florida·Phase 3·NCT03092375·177 enrolled

Insulin resistance2 trials

Extrahepatic Insulin Resistance in Chronic Hepatitis C

Completed·UUniversity Hospital, Geneva·N/A·NCT02760355·17 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Completed· Roche logo

Roche·Phase 4·NCT00545233·155 enrolled

Oral2 trials

A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets

Completed· Roche logo

Roche·Phase 1·NCT01697436·40 enrolled

Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease

Completed·—·Phase 4·NCT02328651·24 enrolled

HCV Infection2 trials

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01846832·232 enrolled

Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection

Unknown status·TTanta University·N/A·NCT02261662·30 enrolled

Efficacy2 trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT02446717·141 enrolled

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Completed· GSK logo

GSK·Phase 3·NCT00411385·933 enrolled

Chronic2 trials

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01945294·257 enrolled

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

Unknown status·NNational Hepatology & Tropical Medicine Research Institute·Phase 3·NCT02771405·150 enrolled

Pediatric1 trial

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00761735·94 enrolled

MPA1 trial

A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01615393·40 enrolled

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01309932·165 enrolled

Adult Subject1 trial

Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition

Completed·FFuture University in Egypt·Phase 1·NCT05532306·36 enrolled

Viral Hemorrhagic Fever1 trial

Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities

Withdrawn·UU.S. Army Medical Research and Development Command·Phase 2·NCT00992693

Trial1 trial

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01054573·90 enrolled

Buprenorphine1 trial

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Completed· AbbVie logo

AbbVie·Phase 2·NCT01911845·38 enrolled

Hemorrhagic Fever With Renal Syndrome1 trial

Ribavirin for Hemorrhagic Fever With Renal Syndrome

Withdrawn·UU.S. Army Medical Research and Development Command·Phase 2·NCT00623168

Interleukin1 trial

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Terminated· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT01459913·239 enrolled

Safety and Efficacy1 trial

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

Completed·TTarek I. Hassanein, M.D., FACP, FAG, AGAF·Phase 4·NCT02304159·39 enrolled

Papilloma1 trial

Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02308241·12 enrolled

Immunodeficiency1 trial

Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000733·42 enrolled

Infection1 trial

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01132313·488 enrolled

Phase 21 trial

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

Completed·BBiolex Therapeutics, Inc.·Phase 2·NCT00863239·116 enrolled

Liver Disease1 trial

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00078403·333 enrolled

Hepatocellular Carcinoma1 trial

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02940496·15 enrolled

Interaction1 trial

A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000772·15 enrolled

Herpangina1 trial

Effect of Recombinant Human Interferon α-2b Spray on Herpangina

Completed·—·Phase 4·NCT03266601·668 enrolled

Unspecified2 trials

Ph IIA Study (SOC +/- NS5B)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01193361·39 enrolled

Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population

Completed·GGetz Pharma·Phase 4·NCT02601976·64 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 31, 1985

VIRAZOLE

NDA NDA018859

Jun 3, 1998

REBETOL

NDA NDA020903

Dec 3, 2002

COPEGUS

NDA NDA021511

Jul 29, 2003

REBETOL

NDA NDA021546

Sources

References

[1]
ClinicalTrials.gov — 517 trial records for Ribavirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Virazole drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ribavirin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ribavirin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021546). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Conrado Roberto Hoffmann Filho company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Inosine-5'-Monophosphate Dehydrogenase 1 Inhibitor; RNA-Directed RNA Polymerase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: CConrado Roberto Hoffmann Filho

Virazole

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis70 trials

Hepatitis C56 trials

Chronic Hepatitis C Virus Infection9 trials

Treatment6 trials

Liver Transplant5 trials

Hepatitis C Virus Infection5 trials

Efficacy and Safety4 trials

Fasting Conditions3 trials

TED3 trials

Combination Therapy3 trials

Phase II2 trials

Randomized2 trials

Insulin resistance2 trials

Oral2 trials

HCV Infection2 trials

Efficacy2 trials

Chronic2 trials

Pediatric1 trial

MPA1 trial

COVID-191 trial

Pneumonia1 trial

Age1 trial

Adult Subject1 trial

Viral Hemorrhagic Fever1 trial

Trial1 trial

Buprenorphine1 trial

Hemorrhagic Fever With Renal Syndrome1 trial

Interleukin1 trial

Safety and Efficacy1 trial

Papilloma1 trial

Immunodeficiency1 trial

Infection1 trial

Phase 21 trial

Liver Disease1 trial

Hepatocellular Carcinoma1 trial

Interaction1 trial

Herpangina1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News